Antonio Messina
A5087016293- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac and Coronary Surgery Techniques
- Cardiac Structural Anomalies and Repair
- Aortic aneurysm repair treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Mechanical Circulatory Support Devices
- Infectious Aortic and Vascular Conditions
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiomyopathy and Myosin Studies
- COVID-19 and healthcare impacts
- Long-Term Effects of COVID-19
- Vascular Procedures and Complications
- Nitric Oxide and Endothelin Effects
- Liver Disease Diagnosis and Treatment
- Epilepsy research and treatment
- Pain Management and Treatment
- Pharmacogenetics and Drug Metabolism
- Osteomyelitis and Bone Disorders Research
- Cardiac Health and Mental Health
- Cardiovascular Issues in Pregnancy
- Bone Metabolism and Diseases
Fondazione Poliambulanza Istituto Ospedaliero
2015-2024
Ideon Innovation (Sweden)
2013
Tromsø research foundation
2013
National Research Tomsk State University
2013
Odense Municipality
2013
University of Verona
2004-2007
Sapienza University of Rome
1987
Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous repair or replacement. Our aim was perform a large-scale analysis examining midterm outcomes ViV ViR.Patients undergoing ViR were enrolled the Valve-in-Valve International Data Registry. Cases performed between March 2006 2020. Clinical endpoints reported according Valve Academic Research Consortium (MVARC) definitions. Significant...
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid (BAV) stenosis is technically challenging and burdened by an increased risk of paravalvular regurgitation (PVR).
Although commonly reported as single-centre experiences, redo aortic valve replacement (RAVR) has overall acceptable results. Nevertheless, trans-catheter recently questioned the efficacy of RAVR. Early-to-mid-term results and determinants mortality in 711 cases RAVR from seven European institutions were assessed entire population selected high-risk subgroups [elderly >75 years, urgent/emergent procedures, preoperative New York Heart Association (NYHA) functional Class IV endocarditis]....
Objective: Controversy still exists about averting expenditure of health care resources on the growing elderly population.This study evaluates clinical outcome patients aged 75 years and older operated upon for acute type A aortic dissection.Methods: Between January 1990 April 2004, 247 undergoing emergency operation dissection at our Institution, 40 (16%) were (mean 78 AE 3 years, range 75-88 years) represent population.On admission, 9 (22.5%) had cardiogenic shock/ hypotension, 20 (50%)...
To evaluate the results of aortic valve replacement through sternotomic approach in redo scenarios (RAVR) vs transapical transcatheter (TAVR), patients eighth decade life or older already undergone previous coronary artery bypass grafting (CABG).One hundred and twenty-six undergoing RAVR were compared with 113 TaTAVR terms 30-day mortality Valve Academic Research Consortium-2 outcomes. The two groups also analysed after propensity-matching.TaTAVR demonstrated a higher incidence (P = 0.03),...
There is a lack of comparative data on transcatheter aortic valve implantation (TAVI) in degenerated surgical prostheses (valve-in-valve [ViV]).
Our unit has used off-pump coronary artery bypass (OPCAB) surgery since 1998, and consequently developed teaching methods for surgical trainees. This study aimed to compare the medium-term results of OPCAB performed by experts or supervised trainees.We retrospectively analysed data relating 1333 operations between January 1998 2006 (mean patient age: 65.3 + - 13; M/F ratio: 2.9), compared outcomes 977 (73.3%) carried out three expert surgeons (group A) with remaining 356 (26.7%) four...
Transcatheter aortic valve replacement (TAVR) in patients with chronic kidney disease (CKD) is challenging due to the high risk of contrast-induced nephropathy (CIN) and acute injury (AKI). AKI dramatically reduces clinical benefit TAVR one strongest predictors 30-day mortality as well long-term adverse outcomes after TAVR. The aim this study was evaluate a protocol specifically designed reduce incidence advanced CKD screened for undergoing TAVR.Twelve consecutive severe stenosis suffering...